Search Results

Total 451 documents found.

•  

• Takeda Expands International Operations Leadership July 30, 2010
• Osaka, Japan, July 30, 2010 -Takeda Pharmaceutical Company Limited ("Takeda") today announced that effective August 1, 2010 the International Operations organization will be further strengthened with the appointment of a Senior Vice President (SVP) responsible for ex-Japan Asia commercial activities. This change will further enhance the company’s structure to accelerate Takeda’s global strategies and enable the management team in each region to most effectively address the local business environment.

• Takeda Announces Appointment of New Corporate Officers June 25, 2010
• Osaka, Japan, June 25, 2010 --- Takeda Pharmaceutical Company Limited (“Takeda”) announced the appointment of new corporate officers which was resolved today at the extraordinary Board of Directors’ Meeting, and the details of the appointment are as follows:

• Takeda to Create Global Centers of Excellence
  Reorganization helps Takeda realize globalization vision March 31, 2009
• Osaka, Japan, March 31, 2009 -Takeda Pharmaceutical Company Limited ("Takeda") today announced a reorganization of its corporate structure, as part of its 2006-2010 Medium-Term Plan vision to become a global pharmaceutical company with highly integrated global operations. In order to become more responsive to rapid changes in the global operating environment and to maximize the global market potential of new products and the company’s global presence, the company is streamlining executive reporting relationships to Yasuchika Hasegawa, President, by creating corporate-level, center of excellence R&D, commercial and administrative functions. Effective April 1, 2009, Shigenori Ohkawa, Ph.D., will become Chief Scientific Officer (CSO), and Alan MacKenzie will become Executive Vice President (EVP) International Operations. Additionally, a Chief Administrative Officer (CAO) role will be established.

• Notice regarding Revision to Increase Interim and Planned Annual Dividends for the Fiscal Year Ending March 31, 2009 November 4, 2008
• Osaka, Japan, November 4, 2008 --- Takeda Pharmaceutical Company Limited ("Takeda") announced that its Board of Directors resolved today revision to increase the interim and planned annual dividends per share for the fiscal year ending March 31, 2009.

• Notice of Upward Revision to First Half Year Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2009 October 20, 2008
• Osaka, Japan, October 20, 2008 --- Takeda Pharmaceutical Company Limited ("Takeda") announced today upward revision to first half year consolidated financial forecasts for fiscal year ending March 31, 2009. Takeda did not provide an updated forecast for the full-year consolidated financial forecasts for fiscal year ending March 31, 2009, as such figures are currently being determined and will be announced on November 4, 2009, at the time of the announcement of first half year financial results.

• Takeda Pharmaceuticals and TAP Pharmaceutical Products Inc. Merge
  Combined Company is a Top 15 Pharmaceutical Company in the United States July 2, 2008
• Osaka, Japan and Deerfield, Ill. – July 1, 2008 (US Time) – Takeda Pharmaceutical Company Limited today announced that Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc. merged with TAP Pharmaceutical Products Inc. (TAP), forming one of the top 15 pharmaceutical companies in the United States.

• Lundbeck and Takeda form Alliance to Develop and Commercialize a Portfolio of Novel Compounds in the US and Japan for the Treatment of Mood and Anxiety Disorders September 5, 2007
• H. Lundbeck A/S and Takeda Pharmaceutical Company Limited today announced a strategic alliance for the exclusive co-development and co-commercialization in the United States and Japan of several compounds in Lundbeck’s pipeline for the treatment of mood and anxiety disorders.

• Takeda to Transfer its Business of Leasing of Office Building to the Consolidated Subsidiary by Corporate Demerger April 26, 2007
• OSAKA, JAPAN, April 26, 2007 --- Takeda Pharmaceutical Company Limited ("Takeda") today announced that Takeda and its wholly owned subsidiary, Takeda Pharmaceutical Real Estate Company Ltd. ("Takeda Estate") approved at their respective Board of Directors' Meetings the demerger transferring Takeda's business of leasing of office building to Takeda Estate.

• XOMA and Takeda Expand Collaboration for Therapeutic Antibody Discovery and Development February 28, 2007
• Berkeley, CA, and Osaka, JAPAN - February 28, 2007 - XOMA Ltd. (Nasdaq: XOMA) and Takeda Pharmaceutical Company Limited (TSE4502:Takeda) announced today they have amended their existing agreement to increase the number of potential therapeutic antibody programs under the collaboration initiated in November of 2006.With this expansion, XOMA estimates the aggregate upfront, R&D funding, milestone and other payments could exceed $230 million before royalties over the life of the agreement. Since entering the original agreement four months ago, XOMA has receivedor is otherwise due approximately $8 million as various collaboration-related payments.

• Termination of License Agreement for Tavocept™ in Japan November 2, 2006
• Tokyo/Osaka, Japan, November 2, 2006 --- ASKA Pharmaceutical Co., Ltd. ("ASKA", Tokyo, Japan) and Takeda Pharmaceutical Company Limited ("Takeda", Osaka, Japan) announced the termination of the License Agreement of March 15, 2006 that had previously been entered into by Takeda, ASKA, KI Pharmaceuticals, Inc.(*) ("KI Pharma", Tokyo, Japan) and BioNumerik Pharmaceuticals, Inc. (San Antonio, Texas, "BioNumerik") with respect to the investigational new drug known as Tavocept™ for the territory of Japan. Tavocept™ (generic name: dimesna) is an investigational new drug with potential for oncology and non-oncology indications that was originated and developed by BioNumerik.

• Takeda and BioNumerik Announce Termination of StrategicAlliance Agreement for Tavocept™ for the U.S. and Canada October 24, 2006
• October 24, 2006, Osaka, Japan and San Antonio, Texas --- Takeda Pharmaceutical Company Limited ("Takeda", Osaka, Japan) and BioNumerik Pharmaceuticals, Inc. ("BioNumerik", San Antonio, Texas) today announced the termination of their License and Development Alliance Agreement for the investigational new drug known as Tavoceptェ for the territories of the United States and Canada.

• Affymax and Takeda Announce Comprehensive Global Agreement for Development and Commercialization of Hematide™ for Anemia
  Companies Will Co-Commercialize with Equal Profit Sharing in the U.S. and Takeda Will Commercialize Outside the U.S. June 27, 2006
• PALO ALTO, Calif., and OSAKA, Japan (June 27 2006), - Affymax, Inc. (Affymax) and Takeda Pharmaceutical Company Limited (Takeda) today announced that the companies have entered into an exclusive global agreement to develop and commercialize Affymax's lead product candidate, Hematide™, for the treatment of anemia. The companies will collaborate on the development of the product and co-commercialize Hematidetrade; in the United States while Takeda will hold an exclusive license to develop and commercialize outside the United States, including the right for Japan under the previous agreement announced in February 2006.

• Cephalon and Takeda Announce Agreement to Co-Promote PROVIGIL® in the United States
  Agreement More Than Doubles Size of PROVIGIL Sales Force June 13, 2006
• Frazer, Pa. and Lincolnshire, Ill. − June 12, 2006 − Cephalon, Inc. (Nasdaq: CEPH) and Takeda Pharmaceuticals North America, Inc. today announced that the companies have entered into an agreement to co-promote PROVIGIL®(modafinil) Tablets [C-IV] in the United States.

• House Foods and Takeda To Conclude a JointVenture Agreement about Takeda Food Products
  "HOUSE WELLNESS FOODS CORPORATION" Starts Operationin April 2006 February 27, 2006
• House Foods Corporation ("House Foods") and Takeda Pharmaceutical Company Limited ("Takeda") announced today that both parties have concluded an agreement to establish a new joint venture "HOUSE WELLNESS FOODS CORPORATION ("new company")". All the business of Takeda Food Products, Ltd. ("Takeda Food") will be transferred to this new company, while the conclusion of the agreement this time follows a basic agreement of both parties announced on December 26, 2005, and subsequent approval by The Japan Fair Trade Commission in view of the antimonopoly act.

• Hitachi and Takeda to Establish "Hitachi Inspharma, Ltd." for Information System Support for Takeda February 20, 2006
• Hitachi, Ltd. ("Hitachi", Tokyo, Japan, President & CEO: Etsuhiko Shoyama) and Takeda Pharmaceutical Company Limited ("Takeda", Osaka, Japan, President & COO: Yasuchika Hasegawa) announced today that both parties established a joint venture  "Hitachi Inspharma, Ltd." for information system support in which Hitachi and Takeda owns 66% and 34% shares respectively.

• TAP LICENSES PREVACID® INTELLECTUAL PROPERTY RIGHTS TO NOVARTIS FOR OTC DEVELOPMENT AND FUTURE COMMERCIALIZATION
  − Agreement Part of TAP's Strategy to Maintain Its Leadershipin Area of Gastroenterological Products − December 21, 2005
• LAKE FOREST, Ill., Dec. 20, 2005 − TAP Pharmaceutical Products Inc. announced today that it has agreed to license its Prevacid® (lansoprazole) trademark and certain other intellectual property to Novartis for development and future commercialization in the over-the-counter (OTC) market. The agreement covers the United States and its territories. Financial terms were not disclosed.

• Takeda to Transfer its Life-environmental Business to Osaka Gas March 30, 2005
• OSAKA, JAPAN −−− Osaka Gas Co., Ltd. ("Osaka Gas", President: Hirofumi Shibano) and Takeda Pharmaceutical Company Limited ("Takeda", President: Yasuchika Hasegawa) jointly announced today the transfer of shares of Takeda's five subsidiaries and affiliates engaged in life-environmental business to Osaka Gas Chemicals Co., Ltd. ("Osaka Gas Chemicals", President: Mitsuo Endo), a subsidiary of Osaka Gas. Such five companies include Japan EnviroChemicals, Ltd. ("Japan EnviroChemicals" President: Atsuo Kobayashi), a wholly owned subsidiary of Takeda.

• Takeda to Acquire Syrrx February 7, 2005
• Takeda Pharmaceutical Company Limited (Osaka, Japan, "Takeda", President and Chief Operating Officer: Yasuchika Hasegawa) announced today that Takeda and Syrrx Inc. (San Diego, CA, "Syrrx", Chairman of the Board: Samuel D.Colella) agreed on February 5, 2005 (PST) to merge Syrrx, Inc. into the Takeda Group. The merger is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and is subject to the satisfaction of other customary closing conditions. Upon successful completion of the transaction, which is anticipated to occur in the first quarter of 2005, Syrrx will become a subsidiary of Takeda America Holdings, Inc., a wholly owned subsidiary of Takeda.

• Takeda to Support Relief Effort forTsunami and Earthquake Disaster in Southeast Asia
  All Takeda employees in the world express their deepest sympathyand condolences to all those affected by this disaster. February 4, 2005
• OSAKA, JAPAN --- Takeda Pharmaceutical Company Limited ("Takeda") announced today that Takeda group companies including subsidiaries/affiliates outside Japan and its employees are now making donation to the Red Cross and other organizations in funds and medicines to relief efforts for tsunami disaster victims in Southeast Asia. The total amount will be estimated approximately Yen 100 million.

• ENBREL® to Treat Rheumatoid Arthritis Approved January 25, 2005
• OSAKA, JAPAN --- Wyeth K.K. and Takeda Pharmaceutical Company Limited ("Takeda") announced today that ENBREL (etanercept) has been approved by the Japan Ministry of Health, Labour and Welfare (MHLW) for the treatment of rheumatoid arthritis (RA) in patients who had an inadequate response to existing therapies. As announced earlier, the product will be co-promoted by both Wyeth K.K. and Takeda.

Pages:[1] [2] [3] [4] [5] [6] [7] [8] [9] [10]   Next